BiBBInstruments’ products are marketed under the brand EndoDrill®. These are disposable biopsy instruments used for cancer diagnosis. The company is developing a product family of several revolutionary instruments that address major clinical needs for the most common forms of cancer in the world. BiBB’s products offer many synergies in the form of common components, regulatory strategy and joint patent protection.
The company’s first product, EndoDrill® GI Upper for sampling deep tumours in the upper gastrointestinal tract, was successfully evaluated in a randomised clinical study in Lund and was launched in autumn 2017. Another instrument for tumours in the upper GI tract, EndoDrill® GI Upper Mini, was launched in May 2018. These instruments were granted an expanded indication in November 2018, and can now be used for tumours in the colon and lungs. EndoDrill® Core Needle is a rigid biopsy instrument with drilling function for performing biopsies in cases of suspected breast cancer. It can also be used for other tumour forms where core needle biopsies are performed, such as the liver, lymph nodes and prostate. EndoDrill® Core Needle was approved for CE-marking in November 2018 and is slated for launch during the first half of 2019. The company’s new instrument, EndoDrill® Model X, differs from the original “drill screw” technology, and BiBB has also filed a separate patent application for this unique design. BiBB plans to launch EndoDrill® Model X in Sweden in 2020.